Information:
Fel:
ID
18188
Beskrivning
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00103506
Länk
https://clinicaltrials.gov/show/NCT00103506
Nyckelord
Versioner (1)
- 2016-10-24 2016-10-24 -
Uppladdad den
24 oktober 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Multiple Myeloma NCT00103506
Eligibility Multiple Myeloma NCT00103506
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Myeloma NCT00103506
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Multiple Myeloma | Prior Therapy Quantity | Disease Response | Progressive Disease | First treatment Primary Refractory
Item
patients with multiple myeloma who have received at least 1 prior therapy and who have either responded and later had progressive disease or have progressed during their first therapy (primary refractory) are eligible for the study
boolean
C0026764 (UMLS CUI [1])
C1514463 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C1704632 (UMLS CUI [3])
C1335499 (UMLS CUI [4])
C1708063 (UMLS CUI [5,1])
C2347678 (UMLS CUI [5,2])
C1514463 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C1704632 (UMLS CUI [3])
C1335499 (UMLS CUI [4])
C1708063 (UMLS CUI [5,1])
C2347678 (UMLS CUI [5,2])
Doxorubicin Cumulative Dose | Doxil | Anthracycline Antibiotics | Caelyx | Epirubicin | Mitoxantrone | Idarubicin
Item
patients who may have received prior doxorubicin but not more than a cumulative dose of 240 milligram per meter square (mg/m^2) doxorubicin, doxil, or the equivalent amount of another anthracycline (i.e., 1 mg doxorubicin = 1 mg doxil/caelyx = 1.8 mg epirubicin = 0.3 mg mitoxantrone = 0.25 mg idarubicin)
boolean
C0013089 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
C0279284 (UMLS CUI [2])
C0003234 (UMLS CUI [3])
C0701183 (UMLS CUI [4])
C0014582 (UMLS CUI [5])
C0026259 (UMLS CUI [6])
C0020789 (UMLS CUI [7])
C2986497 (UMLS CUI [1,2])
C0279284 (UMLS CUI [2])
C0003234 (UMLS CUI [3])
C0701183 (UMLS CUI [4])
C0014582 (UMLS CUI [5])
C0026259 (UMLS CUI [6])
C0020789 (UMLS CUI [7])
Cardiac function | Left ventricular ejection fraction
Item
must have normal cardiac function, as evidenced by a left lvef within institutional normal limits.
boolean
C0232164 (UMLS CUI [1])
C0428772 (UMLS CUI [2])
C0428772 (UMLS CUI [2])
Velcade | Anthracycline Antibiotics | Progressive Disease
Item
history of treatment with velcade or progressive disease while receiving an anthracycline-containing regimen
boolean
C1174739 (UMLS CUI [1])
C0003234 (UMLS CUI [2])
C1335499 (UMLS CUI [3])
C0003234 (UMLS CUI [2])
C1335499 (UMLS CUI [3])
First line treatment Disease No status change
Item
no change in disease status during initial therapy
boolean
C1708063 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
C0442739 (UMLS CUI [1,3])
C0012634 (UMLS CUI [1,2])
C0442739 (UMLS CUI [1,3])
Malignant Neoplasm untreated | Multiple Myeloma | Anthracycline Antibiotics | Progressive Disease
Item
no treatment for malignancy within past 5 yrs (other than multiple myeloma) or progressive disease while receiving anthracycline-containing regimen
boolean
C0006826 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0026764 (UMLS CUI [2])
C0003234 (UMLS CUI [3])
C1335499 (UMLS CUI [4])
C0332155 (UMLS CUI [1,2])
C0026764 (UMLS CUI [2])
C0003234 (UMLS CUI [3])
C1335499 (UMLS CUI [4])
Non-secretory myeloma
Item
non-secretory disease
boolean
C0456845 (UMLS CUI [1])
Myocardial Infarction
Item
myocardial infarct within past 6 months
boolean
C0027051 (UMLS CUI [1])
major surgery
Item
no major surgery in past 30 days.
boolean
C0679637 (UMLS CUI [1])